Praxis (NASDAQ: PRAX) COO adds shares through Employee Stock Purchase Plan

Rhea-AI Filing Summary

Praxis Precision Medicines Chief Operating Officer acquires shares through employee plan. Megan Sniecinski acquired 89 shares of Praxis Precision Medicines common stock at an effective price of $167.943 per share under the company’s Employee Stock Purchase Plan. Following this acquisition, she directly holds 28,664 common shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sniecinski Megan

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	89	$167.943	$15K

Holdings After Transaction: Common Stock — 28,664 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares acquired: 89 shares Price per share: $167.943 per share Post-transaction holdings: 28,664 shares

3 metrics

Shares acquired 89 shares Common stock acquired on 2026-05-14

Price per share $167.943 per share Effective transaction price under ESPP

Post-transaction holdings 28,664 shares Common shares directly held after acquisition

Key Terms

Employee Stock Purchase Plan, Rule 16b-3(d), Rule 16b-3(c), Form 4

4 terms

Employee Stock Purchase Plan financial

"These shares were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Rule 16b-3(d) regulatory

"transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)"

Rule 16b-3(d) is a narrow SEC safe-harbor that shields company insiders (officers, directors and large shareholders) from liability for short‑swing profits when their buys or sells of company stock are made under a pre-established, written plan or contract that removes the insider’s ability to time trades. For investors, this matters because it permits predictable, automated insider transactions — like scheduled sales for diversification or payroll withholding — without triggering forced disgorgement, so such planned trades are treated differently from opportunistic insider trading.

Rule 16b-3(c) regulatory

"transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)"

An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sniecinski Megan

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		A(1)		89	A	$167.943	28,664	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Remarks:

	/s/ Alex Nemiroff, as Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Praxis Precision Medicines (PRAX) report for Megan Sniecinski?

Praxis Precision Medicines reported that Chief Operating Officer Megan Sniecinski acquired 89 shares of common stock. The shares were obtained through the company’s Employee Stock Purchase Plan, reflecting a routine, compensation-related acquisition rather than an open-market purchase.

At what price did Megan Sniecinski acquire Praxis Precision Medicines (PRAX) shares?

Megan Sniecinski acquired 89 Praxis Precision Medicines common shares at an effective price of $167.943 per share. This price reflects the transaction value reported for shares purchased under the company’s Employee Stock Purchase Plan in the Form 4 filing.

How many Praxis Precision Medicines (PRAX) shares does Megan Sniecinski now hold?

After the reported transaction, Megan Sniecinski directly holds 28,664 shares of Praxis Precision Medicines common stock. This total includes the 89 shares recently acquired through the Employee Stock Purchase Plan, as disclosed in the Form 4 insider transaction report.

What plan was used for Megan Sniecinski’s Praxis Precision Medicines (PRAX) share acquisition?

The acquisition was made under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan. The Form 4 footnote explains these ESPP transactions were exempt under Rule 16b-3(d) and Rule 16b-3(c), indicating they are standard, plan-based insider purchases.

Was Megan Sniecinski’s Praxis Precision Medicines (PRAX) transaction an open-market buy?

No, the transaction was not an open-market buy. Megan Sniecinski acquired 89 shares through the company’s Employee Stock Purchase Plan, a structured benefit program, with the filing noting exemptions under Rule 16b-3(d) and Rule 16b-3(c) for these plan-related transactions.